Germany
· Delayed Price · Currency is EUR | Market Cap | 11.61B |
| Revenue (ttm) | 4.00B |
| Net Income (ttm) | -891.81M |
| Shares Out | n/a |
| EPS (ttm) | -5.61 |
| PE Ratio | n/a |
| Forward PE | 18.87 |
| Dividend | 2.89 (3.93%) |
| Ex-Dividend Date | Jun 25, 2024 |
| Volume | 73 |
| Average Volume | 676 |
| Open | 73.59 |
| Previous Close | 72.02 |
| Day's Range | 73.48 - 73.67 |
| 52-Week Range | 62.00 - 150.56 |
| Beta | 1.13 |
| RSI | 54.56 |
| Earnings Date | Apr 25, 2025 |
About Illumina
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole... [Read more]
Financial Performance
In 2024, Illumina's revenue was $4.37 billion, a decrease of -2.93% compared to the previous year's $4.50 billion. Losses were -$1.22 billion, 5.34% more than in 2023.
Financial numbers in USD Financial StatementsNews
Illumina Analysts Lower Their Forecasts After Q1 Results
Illumina, Inc. (NASDAQ: ILMN) reported upbeat earnings for the first quarter, but lowered its FY25 guidance, after the closing bell on Thursday. The company posted quarterly earnings of 97 cents per ...
Illumina Analysts Lower Their Forecasts After Q1 Results
Illumina, Inc. ILMN reported upbeat earnings for the first quarter, but lowered its FY25 guidance, after the closing bell on Thursday.
Illumina: Multiple Headwinds Point To Limited Upside In 2025
Illumina outlines $4.18B to $4.26B guidance for 2025 amid China headwinds and strategic cost reductions
Illumina, Inc. (ILMN) Q1 2025 Earnings Call Transcript
Illumina down 3% as lowered 2025 EPS guidance overshadows Q1 top-line beat
Illumina and Ovation.io launching first-of-kind GLP-1 dataset to accelerate new therapy development
First real-world dataset with integrated clinical and multiomic insights from 25,000 patients treated with GLP-1 therapies Dataset will advance development of GLP-1 therapies in new indications and ac...
Rep. Thomas Kean Has Bought Up to $45K Worth Of Illumina Stock: Here's What You Should Know
April 18, 2025 records indicate that Representative Thomas Kean filed a purchase of Illumina (NASDAQ: ILMN), valued between $3,003 and $45,000. According to the April filing, the transaction occurred...
Target Validation for Genetic Targets Innovation Research Report 2025: 14,172 Deals Totaling $11.4 Billion - BGI biotech and illumina are Among the Leaders with Strong Portfolios
Dublin, April 18, 2025 (GLOBE NEWSWIRE) -- The "Innovation Insights: Target validation for genetic targets" report has been added to ResearchAndMarkets.com's offering.
Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation
Collaboration accelerates insights on clinical benefits of molecular profiling across all major categories of disease SAN DIEGO and CHICAGO , April 15, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN...
Illumina to Announce First Quarter 2025 Financial Results on Thursday, May 8, 2025
SAN DIEGO , April 10, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2025 following the close of market on Thursday, May 8, 2025. O...
Snowflake Unveils Apache Iceberg™ Innovations, Giving Enterprises the Best of Open Data and AI-Ready Performance
Customers now get the best of both worlds: Iceberg’s flexibility and interoperability coupled with Snowflake’s powerful platform to make their data easy, connected, and trusted Thousands of customers ...
Apple To $250? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page . Citigroup...
Corvexs Meister joins the board at Illumina. Heres how he can create value for shareholders
Keith Meister, Corvex Management's chief investment officer, will join Illumina's board starting March 28. He's no stranger to the world of biotech.
Is Illumina Undervalued After An 83% Drop In Its Stock Price?
Illumina rises after board revamp
Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors
Stephen MacMillan to retire from the Board SAN DIEGO , March 25, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced cha...
Activist investor Keith Meister to join Illumina's board, WSJ reports
Activist investor Keith Meister will join the board of gene-sequencing maker Illumina , and current board member Scott Gottlieb will become chairman, the Wall Street Journal reported on Tuesday, citin...
Activist Investor Meister to Join Illumina's Board
Keith Meister's hedge fund Corvex Management has a 2.5% stake in the gene-sequencing machine maker.
Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen
On Friday, March 21, 2025, the Cathie Wood -led Ark Invest made some notable trades, including significant buys and sells. Ark Invest's fund bought Iridium Communications Inc. (NASDAQ: IRDM), Beam Th...
Alliance for Genomic Discovery completes 250,000 whole genomes to accelerate drug discovery
Creates one of the largest, most comprehensive clinical genomic datasets of its kind; multiomic data to be added in next phase of program AGD members are using the population-level insights to u...
Jim Cramer Says Illumina Is 'Challenged,' Recommends Selling This Industrial Stock
On CNBC's “ Mad Money Lightning Round, “ Jim Cramer recommended selling NANO Nuclear Energy Inc. (NASDAQ: NNE). On March 7, NANO Nuclear Energy announced that Florent Heidet, Ph.D. has joined NANO Nu...
Lightning Round: Nano Nuclear Energy is a sell, says Jim Cramer
'Mad Money' host Jim Cramer weighs in on stocks including: Illumina, Nano Nuclear Energy, Steris, Lam Research, Arista Networks and more.
Goldman Sachs Gains Confidence In Market Rebound, Upgrades GE Healthcare Amid China Recovery Hopes
Last week, U.S. President Donald Trump vowed to impose a 25% tariff on imported goods from Mexico and Canada and to double tariffs on those from China to 20% . China responded to Trump’s recent tariff...
Diagnostic Kit Maker Illumina To Cut $100 Million In Costs, Lowers 2025 Profit Outlook Amid China Trade Restrictions
On Monday, Illumina Inc. (NASDAQ: ILMN) said that it is implementing cost cuts of approximately $100 million in fiscal year 2025 in response to China's recent ban on importing its sequencers . Last w...